Shanghai Saints Sages Surgical Co., Ltd. (“Saints Sages”) recently has announced the completion of the Series B funding, Qiming Venture Partners (启明创投) is the largest institutional investor.
Saints Sages is a high-tech enterprise specializing in the research and development and production of surgical energy devices. It mainly engages in the research and development, production, and sales of surgical energy devices. Its products are widely applicable to departments such as minimally invasive surgery, hepatobiliary surgery, gynecology, urology, and thoracic surgery, and have complete core intellectual property rights in related product fields.
According to Saints Sages, its core product SA10 ultrasonic surgery advanced system integrating intelligent algorithms, transducers, and cutting heads to achieve full consumables of ultrasonic knives. Loaded with RTTE II (Real Time Tissue Effect 2nd Generation) algorithm, optimize surgical fluency for a better clinical experience.
According to Frost & Sullivan, the global surgical energy devices market was worth USD 9.1 billion in 2022 and is expected to reach USD 13.06 billion by 2028, with a compound annual growth rate of 6.2%. This growth is driven by the increasing population size, the aging problem, as well as the promulgation of relevant policies in the surgical energy devices industry.
In addition to Saints Sages, many companies are competing in the surgical energy devices market, such as Mechan Electronic Technology (美创医疗), Bonss Medical (邦士医疗), Forerunner Medical (方润医疗), Jeswis Technology (杰西科技), Nanos Medical (莱诺医疗) in China, Johnson & Johnson, ArthroCare in the United States, Medtronic in Ireland, and Smith & Nephew in England.
Zhe Hu, founder and president of Saints Sages, stated: " We hope that with the assistance of capital, we can accelerate the expansion of Saints Sages in the field of surgical energy devices, accelerate the transformation and implementation of medical and industrial integration achievements, enhance the core competitiveness of products and services, comprehensively promote the marketing model driven by technology and academia, enable people to use innovative medical products in the first place and promote them globally. “
This round of financing for Saints Sages was exclusively invested by Qiming Venture Partners (启明创投). This round of financing funds will mainly be used for innovative product research and development, global marketing promotion, and automated production line construction.